ArticleTherapeutic advances in medical oncology2023

Comment on 'Population-adjusted indirect treatment comparison of maintenance PARP inhibitor with or without bevacizumab

Hidekatsu Nakai et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.